Introduction
============

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint pain, fatigue, and even loss of certain crucial physical functions. Disease-modifying antirheumatic drugs are standard care for RA. Recent studies have shown that interleukin 6 (IL-6) plays an important role in inflammation. IL-6 is a membrane receptor produced by cells such as lymphocytes and monocytes, as well as other cell types. IL-6 activates T cells and catalyses B cell proliferation. IL-6 also stimulates osteoclast differentiation, leading to joint destruction.

Tocilizumab (TCZ) is a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody. TCZ can bind to either soluble or membrane-bound IL-6 receptors. When bound, TCZ blocks the IL-6 receptor and prevents or decreases inflammation. It has been approved by the FDA for use in patients diagnosed with moderate to severe rheumatoid arthritis.[@b1-oarrr-4-087] The purpose of this article is to review the effect that TCZ has on patients' physical function, quality of life (QoL), level of fatigue, and sleep patterns.[@b1-oarrr-4-087],[@b2-oarrr-4-087]

Materials and methods
=====================

As seen in [Figure 1](#f1-oarrr-4-087){ref-type="fig"}, a systematic review of TCZ was undertaken with the following keywords used as criteria for the search: TCZ, clinical trial, rheumatoid arthritis, human, and English. Also of interest were the following: health-related quality of life, activities of daily living, quality of life, fatigue, sleep, Health Assessment Questionnaire Disability Index (HAQ-DI), Short Form 36 (SF-36), European Quality of Life-5 Dimensions (EQ-5D), Functional Assessment of Chronic Illness Therapy (FACIT), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Exclusions included reviews, editorials, non-RA studies, case series, and randomized non-trials that did not produce quantifiable data for any one of the following factors: functionality, QoL, fatigue, or sleep. PubMed and the Cochrane databases were queried and bibliographies in all articles were examined. Two individuals extracted data independently from the final articles and any disagreements regarding whether or not the articles stayed within the criteria were discussed. An agreement was reached, resulting in eight relevant articles.

Because randomized controlled trials (RCTs) are of higher quality, this review concentrates on the RCTs, while the remaining open-label trials are used for support. For one domain, sleep, only a single, open-label study was available.

[Table 1](#t1-oarrr-4-087){ref-type="table"} describes the validated measures of function, quality of life, fatigue, and sleep used in this study.[@b3-oarrr-4-087]--[@b10-oarrr-4-087]

Results and discussion
======================

[Table 2](#t2-oarrr-4-087){ref-type="table"} reviews the eight RCTs included in the systematic review.[@b1-oarrr-4-087],[@b2-oarrr-4-087],[@b11-oarrr-4-087]--[@b16-oarrr-4-087] They include 2617 TCZ-treated patients and 1271 controls. Most of the patients were followed in 24-week studies, while one study was 16 weeks, one was 52 weeks, and one was 12 weeks. The patients were quite heterogeneous, with disease duration lasting from less than one year to more than eleven years. Patients had used a wide variety of background therapy and/or previous medications. The background therapies ranged from an 8 mg per week dosage of methotrexate to having had an incomplete response to two tumor necrosis factor inhibitors. Nonetheless, all of the patients' RA activity was very vigorous, with disease activity scores, using 28 joint counts, between 6.1 and 6.8. This degree of heterogeneity precludes a credible meta-analysis.

[Table 3](#t3-oarrr-4-087){ref-type="table"} displays the results of the health questionnaires' disability index (HAQ-DI) responses in the eight RCTs, where such data were available.[@b1-oarrr-4-087],[@b2-oarrr-4-087],[@b11-oarrr-4-087],[@b13-oarrr-4-087]--[@b17-oarrr-4-087] TCZ improved the HAQ-DI score statistically in comparison to the controls, with odds ratios from 1.4 to 7.0, favoring TCZ. The percent of patients who improved more than the MCIDs (≥0.22) were noted in four studies, and the TCZ groups improved by at least that amount in 60%--68% of the patients, compared to 32%--48% of the controls. It is clear that TCZ improves disease-related function significantly and more frequently than the controls, in turn making the amount of improvement clinically important. Open-label studies using TCZ supported the RCT findings. HAQ-DI normalization (\<0.5) occurred in 23%--48% of TCZ-treated patients in four trials.[@b18-oarrr-4-087]--[@b22-oarrr-4-087]

[Table 4](#t4-oarrr-4-087){ref-type="table"} displays the results regarding QoL (SF-36). There were only two double-blind RCTs of TCZ that described this measure.[@b1-oarrr-4-087],[@b2-oarrr-4-087] The Physical Component Summary comprises[@b4-oarrr-4-087] the four domains of the SF-36 pertaining to physical function, and it is statistically clear that TCZ improved this measure substantially more than the MCID (5 units) -- 8.9 and 9.7 -- compared to 4.1 and 5.0 for controls. Unusually, TCZ also statistically improved the Mental Component Summary[@b4-oarrr-4-087] versus control, implying that TCZ may have a positive effect on mood and mental status. As for the HAQ-DI, it is reasonably clear that TCZ both physically and mentally improves QoL in patients diagnosed with RA. The strength of this conclusion is less than that for the HAQ-DI, because there are only two controlled studies measuring QoL.

Fatigue is very common among RA patients. The prevalence rates for fatigue in RA range from 42% to 80%. By using the Checklist of Individual Strength (CIS), persistent severe fatigue is found in 40% of RA patients (according to the FDA). [Table 4](#t4-oarrr-4-087){ref-type="table"} also shows the results regarding fatigue in the two double-blind RCTs in which it was measured.[@b1-oarrr-4-087],[@b2-oarrr-4-087] As for QoL, the patients' feelings of fatigue improved substantially more than the MCID, when compared to the control patients. The open-label studies support the conclusions stemming from the randomized trials, with 7 and 9 units of improvement.[@b22-oarrr-4-087],[@b23-oarrr-4-087] Overall, this important aspect of fatigue associated with RA seems to change favorably when TCZ is used.

Rheumatoid arthritis also affects patients' quality of sleep. This may be due to pain, mood changes, and/or disease activity. There was only one published study, an open-label study, that reported the effects of TCZ on sleep.[@b22-oarrr-4-087] This study used the PSQI and ESS instruments. It showed that patients reported better quality of sleep after taking just two doses of TCZ. No prior sleeping medications were used in this study, so the results are ascribable to the use of TCZ alone. Using the ESS, sleep improved from 7.7 (3.1) to 3.4 (2.2); using the PSQI, it improved from 8.7 (3.3) to 6.7 (4.3). Both changes are more than the MCID's. Nonetheless, because these data originate from an open-label study, these results should be interpreted with caution.

Conclusion
==========

Based on a systematic review supplemented by the RCTs and open-label studies, TCZ improves function and quality of life, and decreases fatigue, in patients with RA; all are probably as important to patients as are joint swelling counts and so forth. It must be noted that sleep, too, may be favorably affected. This supports the general efficacy of TCZ in RA, as demonstrated through conventional measures such as joint tenderness and swelling, and through combined indices such as the ACR response criteria or the 28 joint counts.[@b1-oarrr-4-087],[@b2-oarrr-4-087],[@b12-oarrr-4-087]--[@b16-oarrr-4-087]
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###### 

Descriptions of the most commonly used measurements of function, quality of life, fatigue, and sleep

  Method                                        Measures                             Domains                                                                                                                                                                                                                                                                                                                                                                        Range      MCID
  --------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------- -------
  HAQ-DI[@b3-oarrr-4-087]                       Health-related physical function     Dressing, rising, eating, walking, hygiene, reach, grip, and daily activity                                                                                                                                                                                                                                                                                                    0 to 3     0.22
  SF-36[@b4-oarrr-4-087]                        Quality of life                      Physical activities, social activities, role functioning due to emotional distress, role functioning due to physical impairment, bodily pain, general mental health, general health perceptions, and vitality                                                                                                                                                                  0 to 100   5--10
  EQ-5D[@b5-oarrr-4-087],[@b6-oarrr-4-087]      Differences in health states in RA   Mobility, self-care, usual activities, pain discomfort and anxiety/depression (mood disorders)                                                                                                                                                                                                                                                                                 0 to 1     --
  FACIT[@b7-oarrr-4-087]--[@b9-oarrr-4-087]     Quality of life                      Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing                                                                                                                                                                                                                                                                                         0 to 100   --
  FACIT-F[@b7-oarrr-4-087]--[@b9-oarrr-4-087]   Fatigue                              13 items on a 0--4 scale; ie, fatigue, weakness, listlessness, tiredness, energy, difficulty starting things, difficulty finishing things, able to do usual activities, need for assistance in doing usual activities, sleeping during the day, too tired to eat, frustration due to feeling too tired to do things you want, limitation of social activity due to tiredness   0 to 52    4
  PSQI[@b10-oarrr-4-087]                        Quality of sleep                     Sleep quality, sleep latency, sleep duration, habitual sleep disturbance, sleep disturbance, use of sleep medication, daytime dysfunction                                                                                                                                                                                                                                      0 to 21    --
  ESS[@b10-oarrr-4-087]                         Sleepiness                           Tendency to fall asleep in certain situations of daily life: reading, watching TV, sitting in public place, sitting in the car as passenger, resting in the afternoon, talking, sitting after lunch, sitting in car after stopping for traffic                                                                                                                                 0 to 24    --

**Abbreviations:** HAQ-DI, Health Assessment Questionnaire Disability Index; SF-36, Short Form 36; EQ-5D, European Quality of Life-5 Dimensions; FACIT, Functional Assessment of Chronic Illness Therapy; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale.

###### 

Description of RCTs

  Study                                               Trial duration   Rx (dose)                      Background therapy                                  n        Disease duration   RF +ve   Baseline DAS28
  --------------------------------------------------- ---------------- ------------------------------ --------------------------------------------------- -------- ------------------ -------- ----------------
  Nishimoto et al[@b11-oarrr-4-087]                   24 wks           TCZ 8.00 mg/kg every 4 weeks   MTX-IR                                              61       8.50 yrs           NA       6.10
  Placebo + MTX 8.00 mg/week                                           64                             8.70 yrs                                            NA       6.20                        
  Maini et al[@b12-oarrr-4-087]                       16 wks           TCZ 2.00 mg/kg                 MTX-IR                                              53       9.19 mos           83.0%    6.48
  TCZ 4.00 mg/kg                                                       54                             9.79 mos                                            72.2%    6.55                        
  TCZ 8.00 mg/kg (every 4 weeks)                                       52                             9.21 mos                                            82.7%    6.43                        
  TCZ 2.00 mg/kg + MTX                                                 52                             9.33 mos                                            88.5%    6.58                        
  TCZ 4.00 mg/kg + MTX                                                 49                             7.82 mos                                            77.6%    6.34                        
  TCZ 8.00 mg/kg + MTX                                                 50                             10.62 mos                                           80.0%    6.47                        
  Placebo + MTX (MTX 10.00--25.00 mg/wk)                               49                             11.24 mos                                           95.9%    6.75                        
  Genovese et al[@b1-oarrr-4-087]                     24 wks           TCZ 8.00 mg/kg + DMARD         DMARD-IR                                            803      9.80 yrs           NA       6.70
  DMARD                                                                413                            9.80 yrs                                            NA       6.60                        
  Jones et al[@b13-oarrr-4-087]                       24 wks           TCZ 8.00 mg/kg every 4 wks     Never failed MTX or biological agents in the past   288      6.40 yrs           NA       6.80
  MTX 7.50 mg/wk (titrated to 20.00 mg/kg at 8 wks)   284              6.20--6.30 yrs                 NA                                                  6.80                                 
  Placebo (first 8 wks), then TCZ for 16 wks          101              NA                             NA                                                  NA                                   
  Emery et al[@b14-oarrr-4-087]                       24 wks           TCZ 8.00 mg/kg + MTX           TNFi-IR                                             170      12.60 yrs          79.00%   6.79
  TCZ 4.00 mg/kg + MTX                                                 161                            11.00 yrs                                           73.00%   6.78                        
  Placebo + MTX                                                        158                            11.40 yrs                                           75.00%   6.80                        
  Nishimoto et al[@b15-oarrr-4-087]                   52 wks           TCZ 8.00 mg/kg every 4 weeks   DMARD-IR or failed immunosuppressant                157      2.20 yrs           NA       6.50
  DMARD                                               145              2.40 yrs                       NA                                                  6.40                                 
  Smolen et al[@b2-oarrr-4-087]                       24 wks           TCZ 4.00 mg/kg + MTX           MTX discontinued ≥12 weeks before study             214      7.40 yrs           78.00%   6.80
  TCZ 8.00 mg/kg + MTX (every 4 wks)                  205              7.50 yrs                       83.00%                                              6.80                                 
  Placebo + MTX (MTX 10.00--25.99 mg/wk)                               204                            7.80 yrs                                            71.00%   6.80                        
  Nishimoto et al[@b16-oarrr-4-087]                   12 wks           TCZ 4.00 mg/kg                 DMARD-IR or failed immunosuppressant                54       7.30 yrs           NA       NA
  TCZ 8 mg/kg (every 4 wks)                           55               8.30 yrs                       NA                                                  NA                                   
  Placebo                                                              53                             8.40 yrs                                            NA       NA                          
  Choy et al[@b17-oarrr-4-087]                        8 wks            TCZ 0.1 mg/kg                  DMARD-IR or failed immunosuppressant                9        17.00 yrs          NA       NA
  TCZ 1 mg/kg                                         9                6.00 yrs                       NA                                                  NA                                   
  TCZ 5 mg/kg                                                          9                              14.00 yrs                                           NA       NA                          
  TCZ 10 mg/kg                                                         7                              13.00 yrs                                           NA       NA                          
  Placebo                                                              11                             14.00 yrs                                           NA       NA                          

**Abbreviations:** TCZ, tocilizumab; MTX, methotrexate; DMARD, disease-modifying antirheumatic drug; RCT, randomized controlled trial.

###### 

Double-blind studies examining HAQ-DI

  Study                               Treatment dose                                    Baseline HAQ-DI                                    Changes from baseline    *P*-value                                        MCID (≥0.22)   *P*-value
  ----------------------------------- ------------------------------------------------- -------------------------------------------------- ------------------------ ------------------------------------------------ -------------- --------------
  Nishimoto et al[@b11-oarrr-4-087]   TCZ                                               NA                                                 NA                       NA                                               67%            *P* \< 0.001
  Control                             NA                                                NA                                                 NA                       34%                                              NA             
  Genovese et al[@b1-oarrr-4-087]     TCZ 8 mg/kg                                       1.50                                               −0.50                    *P* \< 0.0001                                    60%            NA
  Placebo + DMARDS                    1.50                                              −0.20                                              NA                       34%[b](#tfn4-oarrr-4-087){ref-type="table-fn"}   NA             
  Jones et al[@b13-oarrr-4-087]       TCZ                                               1.50                                               −0.70                    NA                                               NA             NA
  MTX                                 1.60                                              −0.50                                              NA                       NA                                               NA             
  Emery et al[@b14-oarrr-4-087]       TCZ 4                                             1.70                                               −0.31                    *P* = 0.003                                      NA             NA
  TCZ 8                               1.70                                              −0.39                                              Less than *P* \< 0.001   NA                                               NA             
  Control                             1.70                                              −0.05                                              NA                       NA                                               NA             
  Nishimoto et al[@b15-oarrr-4-087]   TCZ 8 mg/kg every 4 weeks                         0.80                                               −0.50                    *P* \< 0.001                                     68%            *P* \< 0.001
  DMARD                               0.90[a](#tfn3-oarrr-4-087){ref-type="table-fn"}   −0.30[a](#tfn3-oarrr-4-087){ref-type="table-fn"}   NA                       40%                                              NA             
  Smolen et al[@b2-oarrr-4-087]       TCZ 4.00 mg/kg                                    1.60                                               −0.52                    *P* = 0.0296                                     61%            NA
  TCZ 8.00 mg/kg                      1.60                                              −0.55                                              *P* = 0.0082             59%                                              NA             
  Control                             1.50                                              −0.34                                              NA                       47%[b](#tfn4-oarrr-4-087){ref-type="table-fn"}   NA             
  Nishimoto et al[@b16-oarrr-4-087]   TCZ 4.00 mg/kg                                    1.00                                               −0.01                    *P* \< 0.0100                                    NA             NA
  TCZ 8.00 mg/kg                      1.00                                              −0.25                                              NA                       NA                                               NA             
  Control                             1.00[a](#tfn3-oarrr-4-087){ref-type="table-fn"}   −0.35[a](#tfn3-oarrr-4-087){ref-type="table-fn"}   NA                       NA                                               NA             
  Choy et al[@b17-oarrr-4-087]        TCZ 0.10 mg/kg                                    2.30                                               −0.30                    NA                                               NA             NA
  TCZ 1.00 mg/kg                      2.40                                              −0.10                                              NA                       NA                                               NA             
  TCZ 5.00 mg/kg                      2.00                                              −0.80                                              NA                       NA                                               NA             
  TCZ 10.00 mg/kg                     2.60                                              −0.60                                              NA                       NA                                               NA             
  Placebo                             2.60[a](#tfn3-oarrr-4-087){ref-type="table-fn"}   −0.10[a](#tfn3-oarrr-4-087){ref-type="table-fn"}   NA                       NA                                               NA             

**Notes:**

Approximately;

HAQ ≥ 0.30.

**Abbreviations:** TCZ, tocilizumab; MTX, methotrexate; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; MCID, minimal clinically important difference.

###### 

Double-blind studies examining SF-36 and FACIT-F

  Study                             Treatment Dose   Baseline FACIT-F   Changes in FACIT-F from baseline   *P*-value                Baseline SF-36 scores   Changes from baseline                                                   
  --------------------------------- ---------------- ------------------ ---------------------------------- ------------------------ ----------------------- ----------------------- --------------- --------------- --------------- ---------------
  Genovese et al[@b1-oarrr-4-087]   TCZ 8.00 mg/kg   NA                 8.0                                *P* \< 0.0001 (\>MCID)   NA                      NA                      8.9             *P* \< 0.0001   5.3             *P* \< 0.0001
  Placebo + DMARDS                  NA               3.6                NA                                 NA                       NA                      4.1                     *P* \< 0.0001   2.3             *P* \< 0.0001   
  Smolen et al[@b2-oarrr-4-087]     TCZ 4.00 mg/kg   27.0               7.3                                *P* = 0.0063 (\>MCID)    31.5                    40.1                    9.7             *P* \< 0.0010   5.7             *P* = 0.0394
  TCZ 8.00 mg/kg                    27.7             8.6                *P* \< 0.0001 (\>MCID)             32.1                     40.9                    9.5                     *P* \< 0.0010   7.3             *P* = 0.0012    
  Control                           26.7             4.0                NA                                 32.3                     39.1                    5.0                     NA              2.7             NA              

**Abbreviations:** SF-36, Short Form 36; FACIT, Functional Assessment of Chronic Illness Therapy; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; TCZ, tocilizumab; MTX, methotrexate; DMARD, disease-modifying antirheumatic drug; MCID, minimal clinically important difference.
